ScreenIn3D secures £225k seed investment to commercialise disease-on-a-chip technology

ScreenIn3D Ltd (S3D), a UK-based developer of advanced disease-on-a-chip technologies, has secured £225,000 in seed investment.

This investment will be used to further advance and commercialise its enabling microfluidic technologies for advanced drug screening and precision oncology.

The £225,000 seed investment in ScreenIn3D was led by Gabriel Investments Ltd (Gabriel-IS), a Glasgow (UK) based investment syndicate that focuses on early-stage Scottish companies. Co-investors included Scottish Enterprise and the University of Strathclyde Inspire Entrepreneurs Fund.

Read more HERE.